Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003464 · ClinicalTrials.gov registry record · Phase 2
Temozolomide in Treating Adults With Newly Diagnosed Primary Malignant Glioblastoma Multiforme
A Phase 2 study of Brain and Central Nervous System Tumors, sponsored by Duke University.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT00003464: Completed Phase 2 study of Brain and Central Nervous System Tumors, sponsored by Duke University.
NCT00003464 is a Phase 2 study of Brain and Central Nervous System Tumors that has completed, run by Duke University. The registered enrollment target is 50 participants, below the 183-participant average among 45 other Brain and Central Nervous System Tumors trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003464, a Phase 2 study of Brain and Central Nervous System Tumors, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of temozolomide in treating adults with newly diagnosed primary malignant glioblastoma multiforme.
Conditions Studied
Interventions
- DRUG temozolomide
- RADIATION radiation therapy
Study Locations (1)
North Carolina
- Duke Comprehensive Cancer Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 1997-09 |
| Est. Completion | 2003-08 |
| Phase | Phase 2 |
What the finished NCT00003464 record still lists
NCT00003464 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 183-participant average among 45 other Brain and Central Nervous System Tumors trials with a reported enrollment target (73% lower).
The record links to 1 condition, with Brain and Central Nervous System Tumors appearing as the primary indexed condition, and to 2 interventions - of which temozolomide is the first listed.
NCT00003464 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT00003464 about?
NCT00003464 is a clinical study titled "Temozolomide in Treating Adults With Newly Diagnosed Primary Malignant Glioblastoma Multiforme". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of temozolomide in treating adults with newly diagnosed primary malignant glioblastoma multiforme.
What is the current status of trial NCT00003464?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 1997-09. Estimated completion is 2003-08.
What conditions does trial NCT00003464 study?
This clinical trial studies the following conditions: Brain and Central Nervous System Tumors.
What interventions are being tested in trial NCT00003464?
The interventions under investigation include: temozolomide (DRUG), radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT00003464?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003464 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain and Central Nervous System Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00003464's enrollment target sits among peer trials
50 24th of 45 higher than 22 of 45 other Brain and Central Nervous System Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Brain and Central Nervous System Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma
ACTIVE NOT RECRUITING · Phase 2
-
Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Evaluating Patients Who Are Undergoing Treatment for Gliomas
COMPLETED · Phase 2
-
Combination Chemotherapy for Patients With Brain Cancer
COMPLETED · Phase 2
-
Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors
COMPLETED · Phase 2
-
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Anaplastic Astrocytoma
COMPLETED · Phase 2
-
Phenylacetate in Treating Children With Recurrent or Progressive Brain Tumors
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia